Front Row Advisors’s Cardiff Oncology CRDF Stock Holding History

Front Row Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1	Buy	+1	New	+$2	﹤0.01%	575
2026 Q1	–	Sell	-1	Closed	-$3	–	558
2025 Q4	$3	Hold	1	–	–	﹤0.01%	553
2025 Q3	$2	Hold	1	–	–	﹤0.01%	552
2025 Q2	$3	Sell	1 -1	-50%	-$3	﹤0.01%	535
2025 Q1	$6	Hold	2	–	–	﹤0.01%	509
2024 Q4	$9	Buy	+2	New	+$6	﹤0.01%	499
2024 Q3	–	Sell	-2	Closed	-$4	–	582
2024 Q2	$4	Hold	2	–	–	﹤0.01%	940
2024 Q1	$11	Hold	2	–	–	﹤0.01%	925
2023 Q4	$3	Hold	2	–	–	﹤0.01%	472
2023 Q3	$3	Hold	2	–	–	﹤0.01%	918
2023 Q2	$0	Hold	2	–	–	﹤0.01%	898
2023 Q1	$0	Buy	+2	New	+$3	﹤0.01%	914
2022 Q2	–	Sell	-2	Closed	–	–	927
2022 Q1	$0	Hold	2	–	–	﹤0.01%	933
2021 Q4	$0	Hold	2	–	–	﹤0.01%	943
2021 Q3	$0	Hold	2	–	–	﹤0.01%	942
2021 Q2	$0	Buy	+2	New	+$17	﹤0.01%	951
2021 Q1	–	Sell	-2	Closed	–	–	958
2020 Q4	$0	Hold	2	–	–	﹤0.01%	913
2020 Q3	$0	Hold	2	–	–	﹤0.01%	927
2020 Q2	$0	Hold	2	–	–	﹤0.01%	995
2020 Q1	$0	Hold	2	–	–	﹤0.01%	988
2019 Q4	$0	Hold	2	–	–	﹤0.01%	917
2019 Q3	$0	Hold	2	–	–	﹤0.01%	949
2019 Q2	$0	Hold	2	–	–	﹤0.01%	1040
2019 Q1	$0	Buy	+2	New	+$7	﹤0.01%	1067

Other funds holding CRDF

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Front Row Advisors's CRDF Position: Q2 2026 in Review

Front Row Advisors opened a new position in Cardiff Oncology (CRDF) in Q2 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #575 among its holdings. This is a return to the name: Front Row Advisors previously reported a position in CRDF as recently as Q4 2025.

Front Row Advisors first reported a position in CRDF in Q1 2019 and has held it in 24 quarters since. The position peaked at $11 in Q1 2024. 105 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.

Front Row Advisors held 1 share of Cardiff Oncology worth $1 as of Q2 2026.
Cardiff Oncology was a new Front Row Advisors position in Q2 2026.
Cardiff Oncology made up ﹤0.01% of Front Row Advisors's portfolio in Q2 2026, its #575 holding.
Front Row Advisors first reported a position in Cardiff Oncology in Q1 2019 and has held it in 24 quarters since.
Front Row Advisors's Cardiff Oncology position peaked at $11 in Q1 2024.
105 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.

Based on Front Row Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.